Comparative Pharmacology
Head-to-head clinical analysis: BRETHINE versus PROVENTIL HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETHINE versus PROVENTIL HFA.
BRETHINE vs PROVENTIL-HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing intracellular cAMP, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Selective beta2-adrenergic receptor agonist, relaxing bronchial smooth muscle via increased intracellular cAMP.
5 mg orally three times daily; may increase to 10 mg if needed; maximum 20 mg daily. Subcutaneous: 0.25 mg, may repeat once in 15-30 minutes (not to exceed 0.5 mg in 4 hours).
2 inhalations (90 mcg each) by oral inhalation every 4 to 6 hours as needed for bronchospasm. For prevention of exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.
None Documented
None Documented
3-8 hours (terminal); shorter in children and smokers; prolonged in hepatic impairment
Terminal elimination half-life is 3.8-6 hours. In patients with hepatic impairment or elderly, half-life may be prolonged, requiring dose adjustment.
Renal: 50-60% as unchanged drug and metabolites; biliary/fecal: 20-30%
Approximately 60-70% of the dose is excreted renally as unchanged drug and metabolites after intravenous administration. Fecal excretion accounts for <10%.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist